Mice with renal-specific alterations of stem cell-associated signaling develop symptoms of chronic kidney disease but surprisingly no tumors

PLoS One. 2024 Mar 21;19(3):e0282938. doi: 10.1371/journal.pone.0282938. eCollection 2024.

Abstract

Previously, we found that Wnt and Notch signaling govern stem cells of clear cell kidney cancer (ccRCC) in patients. To mimic stem cell responses in the normal kidney in vitro in a marker-unbiased fashion, we have established tubular organoids (tubuloids) from total single adult mouse kidney epithelial cells in Matrigel and serum-free conditions. Deep proteomic and phosphoproteomic analyses revealed that tubuloids resembled renewal of adult kidney tubular epithelia, since tubuloid cells displayed activity of Wnt and Notch signaling, long-term proliferation and expression of markers of proximal and distal nephron lineages. In our wish to model stem cell-derived human ccRCC, we have generated two types of genetic double kidney mutants in mice: Wnt-β-catenin-GOF together with Notch-GOF and Wnt-β-catenin-GOF together with a most common alteration in ccRCC, Vhl-LOF. An inducible Pax8-rtTA-LC1-Cre was used to drive recombination specifically in adult kidney epithelial cells. We confirmed mutagenesis of β-catenin, Notch and Vhl alleles on DNA, protein and mRNA target gene levels. Surprisingly, we observed symptoms of chronic kidney disease (CKD) in mutant mice, but no increased proliferation and tumorigenesis. Thus, the responses of kidney stem cells in the tubuloid and genetic systems produced different phenotypes, i.e. enhanced renewal versus CKD.

MeSH terms

  • Adult
  • Animals
  • Carcinoma, Renal Cell* / genetics
  • Carcinoma, Renal Cell* / pathology
  • Humans
  • Kidney Neoplasms* / genetics
  • Kidney Neoplasms* / pathology
  • Mice
  • Proteomics
  • Renal Insufficiency, Chronic* / genetics
  • Stem Cells / metabolism
  • beta Catenin / metabolism

Substances

  • beta Catenin

Grants and funding

The study received financial and material support from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany, and financial support from the Urological Research Foundation (Stiftung Urologische Forschung), Berlin, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received a salary from the MDC, except for A.M. (doctoral position) and A.F. (postdoctoral position) who received a salary/scholarship from the Urological Research Foundation, and except for L.C.P. who received a salary from the Utrecht University, Utrecht, The Netherlands. In addition, A.M. received a 3-month salary (extension) from the MDC.